FDA Approves Pacritinib for Myelofibrosis
FDA Approves Ciltacabtagene Autoleucel for R/R Multiple Myeloma
ACS National Consortium Releases Recommendations to Increase Screening
FDA Approves FoundationOne®CDx to Identify MSI-H Solid Tumors
Servier Announces New NDC Number for Ivosidenib
FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma
FDA Approves Illuccix for Prostate Cancer Imaging
GSK Launches Target the Future for the Multiple Myeloma Community
FDA Approves NGS-Based CDx for Non-Small Cell Lung Cancer
New CMS Data Shows Increased Medicare Telemedine Utilization During COVID-19
FDA Approves FoundationOne®CDx as a Companion Diagnostic in Melanoma
LeanTaaS Announces Transform Virtual Summit
FDA Approves Rituximab + Chemotherapy for Pediatric Cancer Indications
FDA Approves Pembrolizumab for IIB or IIC Melanoma Following Complete Resection
FDA Approves Daratumumab and Hyaluronidase-fihj in Combination for MM
Updates to Roundtable on CMS Innovation Center Health Equity Strategy
FDA Approves Pafolacianine for the Detection of Ovarian Cancer Lesions
FDA Approves Sirolimus Protein-Bound Particles for PEComa
FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
U.S. MSTF Releases New Colorectal Cancer Screening Recommendation
FDA Approves Ropeginterferon Alfa-2b-NJFT for Polycythemia Vera
CMS Releases Final Rule to the Radiation Oncology Model
FDA Grants Accelerated Approval to Asciminib for Chronic Myeloid Leukemia
Adaptive Biotechnologies Launches Enhanced Assay Reports for Patients with CLL
FDA Approves Atezolizumab as Adjuvant Treatment for NSCLC
FDA Approves Pembrolizumab Combination for Cervical Cancer
FDA Approves Abemaciclib with Endocrine Therapy for Early Breast Cancer
FDA Approves Brexucabtagene Autoleucel for R/R B-Cell Precursor ALL
G1 Therapeutics Announces J-Code for Trilaciclib
FDA Expands Cetuximab in Combination Label for Metastatic Colorectal Cancer
